Compare NTST & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTST | ELVN |
|---|---|---|
| Founded | 2019 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 2020 | 2020 |
| Metric | NTST | ELVN |
|---|---|---|
| Price | $20.57 | $42.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | $22.02 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 1.2M | 641.7K |
| Earning Date | 04-20-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.28% | N/A |
| EPS Growth | ★ 150.00 | 3.17 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $195,006,000.00 | N/A |
| Revenue This Year | $19.03 | N/A |
| Revenue Next Year | $16.25 | N/A |
| P/E Ratio | $345.08 | ★ N/A |
| Revenue Growth | ★ 19.79 | N/A |
| 52 Week Low | $15.37 | $14.79 |
| 52 Week High | $21.30 | $48.53 |
| Indicator | NTST | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 54.73 | 55.07 |
| Support Level | $19.98 | $16.84 |
| Resistance Level | $21.24 | $48.53 |
| Average True Range (ATR) | 0.33 | 2.29 |
| MACD | -0.02 | -0.51 |
| Stochastic Oscillator | 66.67 | 44.44 |
Netstreit Corp is an internally managed real estate investment trust. The company acquires, owns, and manages single-tenant, retail commercial real estate subject to long-term net leases with high-credit quality tenants across the United States. It focuses on tenants in industries where a physical location is critical to the generation of sales and profits, with a focus on necessity goods and essential services in the retail sector, including home improvement, auto parts, drug stores and pharmacies, general retail, grocers, convenience stores, discount stores, and quick-service restaurants. Majorily operates in U.S. States and Other counties, and derives maximum of revenue from USA.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.